Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET).
Fiche publication
Date publication
novembre 2019
Journal
Angiogenesis
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LUPORSI Elisabeth, Dr LORGIS Véronique, Dr JOUANNAUD Christelle
Tous les auteurs :
Vasseur A, Cabel L, Tredan O, Chevrier M, Dubot C, Lorgis V, Jacot W, Goncalves A, Debled M, Levy C, Ferrero JM, Jouannaud C, Luporsi E, Mouret-Reynier MA, Dalenc F, Lemonnier J, Savignoni A, Tanguy ML, Bidard FC, Pierga JY
Lien Pubmed
Résumé
Proof of concept studies has reported that circulating endothelial cell (CEC) count may be associated with the outcome of HER2-negative metastatic breast cancer (mBC) patients treated by chemotherapy and the anti-VEGF antibody bevacizumab. We report the results obtained in an independent prospective validation cohort (COMET study, NCT01745757).
Mots clés
Bevacizumab, Breast cancer, Circulating endothelial cells
Référence
Angiogenesis. 2019 Nov 26;: